Source comparison
How to Run Thymosin Alpha-1 Cycle: Dosing Comparison
Standard Immune Support 1.6mg Twice weekly (Mon/Thu) 8–12 weeks Acute infection recovery, post-surgical immune function Most commonly used in clinical trials. Established safety profile and consistent immune marker improvements Extended Immune Modulation 12–16
This comparison does not assign a generated winner or score.
- Standard Immune Support
- 1.6mg
- Twice weekly (Mon/Thu)
- 8–12 weeks
- Acute infection recovery, post-surgical immune function
- Most commonly used in clinical trials. Established safety profile and consistent immune marker improvements
- Extended Immune Modulation
- 12–16 weeks
- Chronic immune dysfunction research, autoimmune condition studies
- Used when baseline immune markers show significant suppression. Longer duration doesn't improve outcomes in healthy subjects
- High-Dose Research Protocol
- 3.2mg
- 6–8 weeks
- Severe immunocompromise research (HIV studies, post-chemotherapy models)
- Rarely used outside oncology or infectious disease research. No evidence that doubling dose improves outcomes in non-compromised subjects
- Maintenance Protocol
- 0.8mg
- Once weekly
- Long-term immune function maintenance after initial cycle
- Used in some European studies but not standard in protocols. Insufficient evidence that it maintains upregulated immune markers